Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF816 and Gefitinib in TKI-naïve EGFR-mutant NSCLC
NCT03292133Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nazartinib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Oct 2017; status: terminated.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03292133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292133.